PEG-MGF
PEG-MGF is a pegylated (polyethylene-glycol-conjugated) construct marketed as a longer-acting version of mechano growth factor, but it has no dedicated peer-reviewed studies in any species — its rationale rests entirely on extrapolation from native MGF/IGF-1Ec biology and generic knowledge of how PEGylation affects peptide pharmacokinetics.
This page is a research-orientation summary, not a dosing guide. For anything beyond general background, read the primary literature or talk to a qualified clinician — specifics like amount, frequency, or administration aren't something we publish here.
What it does & how it works
PEG-MGF is conceived as the C-terminal 'E domain' fragment of the mechano growth factor (IGF-1Ec) splice variant, chemically conjugated to polyethylene glycol (PEG). PEGylation is a well-established chemistry technique that increases a molecule's hydrodynamic size, reducing renal clearance and proteolytic degradation and thereby prolonging circulating half-life relative to the unconjugated peptide — however, this is a generic effect of PEGylation observed with other peptides, not something that has been formally measured for MGF itself. The biological mechanism proposed for PEG-MGF (local satellite-cell activation) is simply the mechanism proposed for native MGF, since no distinct mechanistic data exist for the PEGylated construct.
Typical results seen in research
No published peer-reviewed studies, in animals or humans, directly test PEG-MGF as a distinct compound; a 2026 systematic review of performance-enhancing peptides explicitly stated there are 'no peer-reviewed clinical studies in humans' for PEG-MGF and that its half-life has never been formally reported in the literature. Any claims about its effects on recovery or muscle hypertrophy are extrapolated from separate studies of native MGF/IGF-1Ec biology and from general pharmacological knowledge of PEGylation, not from direct study of PEG-MGF itself; reports of its effects in people currently exist only as anecdotal, non-peer-reviewed accounts.
How it’s commonly used
PEG-MGF is used in research and self-experimentation contexts via injection, typically subcutaneous or intramuscular, consistent with the local tissue action proposed for MGF, but no formal pharmacological study has established or validated an administration protocol.
- Frontiers in Endocrinology (Lausanne) · 2026 The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration
Curated from published literature for research orientation. Not an exhaustive review, and not a substitute for reading primary sources.